Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheterization, Swan-Ganz | 1 | 2019 | 86 | 0.630 |
Why?
|
| Thrombocythemia, Essential | 1 | 2019 | 113 | 0.590 |
Why?
|
| Vocal Cord Paralysis | 1 | 2020 | 272 | 0.560 |
Why?
|
| Thrombelastography | 4 | 2016 | 187 | 0.520 |
Why?
|
| Thrombectomy | 1 | 2020 | 703 | 0.500 |
Why?
|
| Endarterectomy, Carotid | 1 | 2020 | 554 | 0.490 |
Why?
|
| Anesthesia, General | 2 | 2020 | 1174 | 0.450 |
Why?
|
| Hemodilution | 1 | 2014 | 120 | 0.440 |
Why?
|
| Blood Preservation | 1 | 2014 | 169 | 0.420 |
Why?
|
| Liver Transplantation | 4 | 2016 | 2332 | 0.410 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2020 | 1462 | 0.390 |
Why?
|
| Liver Failure | 1 | 2013 | 250 | 0.370 |
Why?
|
| Intraoperative Complications | 2 | 2016 | 1164 | 0.350 |
Why?
|
| Blood Coagulation | 3 | 2016 | 1156 | 0.310 |
Why?
|
| Catheterization, Central Venous | 1 | 2013 | 526 | 0.310 |
Why?
|
| Fibrinogen | 2 | 2014 | 888 | 0.270 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3744 | 0.270 |
Why?
|
| End Stage Liver Disease | 2 | 2016 | 352 | 0.270 |
Why?
|
| Thrombosis | 1 | 2019 | 2944 | 0.240 |
Why?
|
| Erythrocytes | 1 | 2014 | 2413 | 0.230 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 3627 | 0.230 |
Why?
|
| Platelet Count | 2 | 2019 | 782 | 0.230 |
Why?
|
| Blood Platelets | 1 | 2014 | 2477 | 0.210 |
Why?
|
| Hemodynamics | 1 | 2013 | 4165 | 0.210 |
Why?
|
| Blood Coagulation Disorders | 2 | 2016 | 350 | 0.210 |
Why?
|
| Hair Follicle | 2 | 2014 | 211 | 0.170 |
Why?
|
| Suction | 1 | 2020 | 266 | 0.160 |
Why?
|
| Recurrent Laryngeal Nerve | 1 | 2020 | 143 | 0.160 |
Why?
|
| Viscoelastic Substances | 1 | 2016 | 20 | 0.130 |
Why?
|
| Blood Coagulation Tests | 2 | 2016 | 271 | 0.130 |
Why?
|
| Vocal Cords | 1 | 2020 | 520 | 0.130 |
Why?
|
| Prothrombin Time | 1 | 2016 | 117 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2019 | 15637 | 0.130 |
Why?
|
| Fibrinolysis | 1 | 2016 | 332 | 0.120 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2019 | 1092 | 0.110 |
Why?
|
| Erythrocyte Count | 1 | 2014 | 157 | 0.110 |
Why?
|
| Hematocrit | 1 | 2014 | 623 | 0.100 |
Why?
|
| Perioperative Care | 1 | 2019 | 1037 | 0.100 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2019 | 991 | 0.100 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2014 | 355 | 0.100 |
Why?
|
| Fibrin | 1 | 2014 | 507 | 0.090 |
Why?
|
| Platelet Activation | 1 | 2014 | 646 | 0.090 |
Why?
|
| Coronary Artery Bypass | 1 | 2019 | 2193 | 0.080 |
Why?
|
| Heart Arrest | 1 | 2019 | 1513 | 0.080 |
Why?
|
| Stem Cells | 2 | 2014 | 3517 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2014 | 2925 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2014 | 1525 | 0.070 |
Why?
|
| Echocardiography | 1 | 2020 | 5006 | 0.070 |
Why?
|
| Temperature | 1 | 2014 | 2219 | 0.070 |
Why?
|
| Movement | 1 | 2014 | 1476 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2020 | 5969 | 0.070 |
Why?
|
| Length of Stay | 1 | 2019 | 6417 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2010 | 487 | 0.060 |
Why?
|
| Humans | 12 | 2020 | 761208 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2020 | 80674 | 0.050 |
Why?
|
| Time Factors | 3 | 2014 | 39957 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2014 | 10422 | 0.040 |
Why?
|
| Middle Aged | 5 | 2020 | 220853 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 64681 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2014 | 11509 | 0.030 |
Why?
|
| Factor X | 1 | 2016 | 64 | 0.030 |
Why?
|
| Skin | 1 | 2010 | 4473 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2014 | 1212 | 0.030 |
Why?
|
| Male | 6 | 2019 | 360693 | 0.030 |
Why?
|
| Female | 6 | 2020 | 392544 | 0.030 |
Why?
|
| International Normalized Ratio | 1 | 2016 | 382 | 0.030 |
Why?
|
| Thromboplastin | 1 | 2016 | 286 | 0.030 |
Why?
|
| Aged | 2 | 2019 | 169288 | 0.030 |
Why?
|
| Tranexamic Acid | 1 | 2016 | 172 | 0.030 |
Why?
|
| Tetracycline | 1 | 2014 | 216 | 0.030 |
Why?
|
| Prognosis | 1 | 2013 | 29687 | 0.030 |
Why?
|
| Antifibrinolytic Agents | 1 | 2016 | 287 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 39126 | 0.020 |
Why?
|
| Living Donors | 1 | 2016 | 643 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2016 | 1303 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 361 | 0.020 |
Why?
|
| Adult | 3 | 2019 | 221119 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 15308 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3608 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 2916 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 74239 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2016 | 54435 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 20119 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2010 | 790 | 0.020 |
Why?
|
| Homeostasis | 1 | 2014 | 3320 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 3726 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 9520 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2010 | 2548 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 9416 | 0.010 |
Why?
|
| Apoptosis | 1 | 2014 | 9477 | 0.010 |
Why?
|
| Models, Biological | 1 | 2014 | 9457 | 0.010 |
Why?
|
| Mice | 2 | 2014 | 81326 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2010 | 14392 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 18926 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 16575 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 22127 | 0.010 |
Why?
|
| Animals | 2 | 2014 | 168079 | 0.010 |
Why?
|
Concepts
(97)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(8)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_